Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Authors
Keywords
Anti-angiogenic, Tyrosine kinase inhibitors, VEGF, Immunotherapy
Journal
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-03-14
DOI
10.1186/s13045-019-0718-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
- (2018) Baohui Han et al. BRITISH JOURNAL OF CANCER
- Antiangiogenic therapies in non-small-cell lung cancer
- (2018) A. Alshangiti et al. Current Oncology
- Anlotinib: First Global Approval
- (2018) Yahiya Y. Syed DRUGS
- Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms
- (2018) Federica Grillo et al. ENDOCRINE-RELATED CANCER
- Regorafenib in the treatment of metastatic colorectal cancer
- (2018) Christelle de la Fouchardière Future Oncology
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
- (2018) Jin Li et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
- (2018) Jun Guo et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
- (2018) Jian Li et al. Journal of Hematology & Oncology
- Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
- (2018) Yu Chen et al. Journal of Hematology & Oncology
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
- (2018) Toni K Choueiri et al. LANCET ONCOLOGY
- EGFR-TKIs resistance via EGFR-independent signaling pathways
- (2018) Qian Liu et al. Molecular Cancer
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors
- (2018) Sam Lubner et al. ONCOLOGIST
- Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
- (2018) Guoshuang Shen et al. Journal of Hematology & Oncology
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Baohui Han et al. JAMA Oncology
- Fruquintinib: First Global Approval
- (2018) Matt Shirley DRUGS
- Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
- (2018) Zihai Li et al. Journal of Hematology & Oncology
- The regulation of cytokine signaling by retinal determination gene network pathway in cancer
- (2018) Xinhua Zheng et al. OncoTargets and Therapy
- Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
- (2018) Masatoshi Kudo Cancers
- Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation
- (2017) Girolamo Ranieri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2017) Kaoru Kubota et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
- (2017) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
- (2017) Rui-Hua Xu et al. Journal of Hematology & Oncology
- Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
- (2017) Xinyang Liu et al. Journal of Hematology & Oncology
- New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
- (2017) Kevin Zarrabi et al. Journal of Hematology & Oncology
- Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review
- (2017) Shan Su et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cells: a novel therapy for solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Pazopanib: a Review in Advanced Renal Cell Carcinoma
- (2017) James E. Frampton Targeted Oncology
- Renal cell carcinoma
- (2017) James J. Hsieh et al. Nature Reviews Disease Primers
- Adjuvant Treatment for High-Risk Clear Cell Renal Cancer
- (2017) Naomi B. Haas et al. JAMA Oncology
- Targeted Therapy for Medullary Thyroid Cancer: A Review
- (2017) S. R. Priya et al. Frontiers in Oncology
- Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
- (2016) Vasileios S. Skouras et al. BIODRUGS
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) Jonathan A Ledermann et al. LANCET
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
- (2016) Nasser H. Hanna et al. LUNG CANCER
- Apatinib — new third-line option for refractory gastric or GEJ cancer
- (2016) Toru Aoyama et al. Nature Reviews Clinical Oncology
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
- (2016) Alain Ravaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma
- (2016) Robert J. Motzer et al. ONCOLOGIST
- Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat
- (2016) Takahiro Seki et al. Nature Communications
- Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. JAMA Oncology
- Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma
- (2015) K. T. Yeung et al. CLINICAL CANCER RESEARCH
- Lenvatinib: First Global Approval
- (2015) Lesley J. Scott DRUGS
- Axitinib: A Review in Advanced Renal Cell Carcinoma
- (2015) Gillian M. Keating DRUGS
- Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis
- (2015) Gillian M. Keating DRUGS
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
- (2015) Y. Zhao et al. ONCOLOGIST
- Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology
- (2015) Sohita Dhillon Targeted Oncology
- Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
- (2015) Sven Mahner et al. Frontiers in Oncology
- Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis
- (2014) K. Kubota et al. ANNALS OF ONCOLOGY
- Ramucirumab: First Global Approval
- (2014) Raewyn M. Poole et al. DRUGS
- Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
- (2014) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of resistance to anti-angiogenesis therapies
- (2013) Sandy Giuliano et al. BIOCHIMIE
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiopoietins in angiogenesis
- (2012) Ernesta Fagiani et al. CANCER LETTERS
- Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
- (2012) Paulo M. Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
- (2012) Hans-Joachim Schmoll et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
- (2011) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
- (2009) Kristy J. Gotink et al. ANGIOGENESIS
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
- (2009) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- (2008) Steven I. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started